AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 7,935.67 ($99.21).
A number of brokerages have commented on AZN. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.75) target price on shares of AstraZeneca in a research note on Monday, January 27th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a £140 ($175.02) target price on shares of AstraZeneca in a research note on Friday, November 22nd.
View Our Latest Report on AstraZeneca
Insiders Place Their Bets
AstraZeneca Trading Up 5.4 %
AstraZeneca stock opened at £117.32 ($146.67) on Thursday. AstraZeneca has a 12 month low of GBX 9,461 ($118.28) and a 12 month high of £133.88 ($167.37). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The stock has a market cap of £181.85 billion, a P/E ratio of 3,724.44, a P/E/G ratio of 0.86 and a beta of 0.17. The company’s fifty day simple moving average is £107.18 and its 200-day simple moving average is £115.04.
About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Read More
- Five stocks we like better than AstraZeneca
- Which Wall Street Analysts are the Most Accurate?
- 3 Must-Have ETFs Set to Dominate This Quarter
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What is the Nasdaq? Complete Overview with History
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.